SEVERAL elucidation developments in the past month have cracked unclose the market for anti-TNF (tumor necrosis factor) alpha therapies.

SEVERAL elucidation developments in the past month have cracked unclose the market for anti-TNF (tumor necrosis factor) alpha therapies, a category with significant bourgeoning potential in the treatment of rheumatoid arthritis (RA) and other indications. Competition has been stirred by way of the early approval of Abbott Laboratories' RA treatment Humira (adalimumab). Meanwhile, after seeing sales hit a ceiling, Amgen's Enbrel appears ready to soar following a viands and Drug Administration (FDA) fresh light for a new manufacturing facility.

There is significant range for growth in the treatment of

...